loading

Galectin Therapeutics Inc (GALT) 最新ニュース

pulisher
Apr 16, 2025

Commonwealth Equity Services LLC Reduces Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - MarketBeat

Apr 16, 2025
pulisher
Apr 15, 2025

Game-Changing MASH Cirrhosis Treatment Results: New Clinical Data Shows Promise in Portal Hypertension - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress - TradingView

Apr 15, 2025
pulisher
Apr 11, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Commonwealth Equity Services LLC - Defense World

Apr 11, 2025
pulisher
Apr 11, 2025

HC Wainwright Analysts Boost Earnings Estimates for GALT - MarketBeat

Apr 11, 2025
pulisher
Apr 09, 2025

FY2029 Earnings Forecast for GALT Issued By HC Wainwright - MarketBeat

Apr 09, 2025
pulisher
Apr 08, 2025

Psoriasis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Apr 08, 2025
pulisher
Apr 07, 2025

Galectin Therapeutics (NASDAQ:GALT) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Apr 07, 2025
pulisher
Apr 07, 2025

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Apr 07, 2025
pulisher
Apr 07, 2025

Q2 EPS Forecast for Galectin Therapeutics Boosted by Analyst - The AM Reporter

Apr 07, 2025
pulisher
Apr 07, 2025

HC Wainwright Analysts Raise Earnings Estimates for GALT - Defense World

Apr 07, 2025
pulisher
Apr 06, 2025

HighTower Advisors LLC Buys Shares of 22,486 Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Apr 06, 2025
pulisher
Apr 05, 2025

Equities Analysts Set Expectations for GALT FY2029 Earnings - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 04, 2025
pulisher
Apr 04, 2025

Galectin Therapeutics (NASDAQ:GALT) Issues Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat

Apr 04, 2025
pulisher
Apr 04, 2025

HC Wainwright Reiterates “Neutral” Rating for Galectin Therapeutics (NASDAQ:GALT) - Defense World

Apr 04, 2025
pulisher
Apr 01, 2025

Galectin Therapeutics Reports Promising 2024 Results - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com

Mar 31, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Breakthrough: Galectin's MASH Drug Shows 68% Disease Reduction in US Patients - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

PNC Financial Services Group Inc. Takes $26,000 Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Galectin Therapeutics (GALT) to Release Quarterly Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 21, 2025

Best Statistical Liver Cirrhosis Market Growth Set to Surge - openPR.com

Mar 21, 2025
pulisher
Mar 14, 2025

Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap up US$10m last week, benefiting both retail investors who own 54% as well as insiders - Simply Wall St

Mar 14, 2025
pulisher
Mar 14, 2025

Public market insider buying at Montero Mining & Explorat (MON) - The Globe and Mail

Mar 14, 2025
pulisher
Mar 08, 2025

While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership - Yahoo Finance

Mar 08, 2025
pulisher
Mar 07, 2025

Sanctuary Advisors LLC Sells 20,700 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Galectin Therapeutics Updates Investors on Clinical Trials - TipRanks

Mar 05, 2025
pulisher
Feb 26, 2025

Galectin Therapeutics shareholders elect directors, ratify auditor - MSN

Feb 26, 2025
pulisher
Feb 20, 2025

Galectin Therapeutics Inc. Reports Positive Additional Results from NAVIGATE TrialOn February 18, 2025, Galectin Therapeutics Inc. (NASDAQ: GALT) announced significant findings from the NAVIGATE trial regarding belapectin, its therapeutic focus on ta - Defense World

Feb 20, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics’ belapectin shows reduction in new varices - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Reports 68% Reduction In New Varices With Belapectin In NAVIGATE Trial U.S. Cohort - Nasdaq

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics IncReports Significant Reduction In New Varices With Belapectin - Marketscreener.com

Feb 18, 2025
pulisher
Feb 18, 2025

Belapectin shows promise in MASH cirrhosis trial - Investing.com India

Feb 18, 2025
pulisher
Feb 18, 2025

Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com South Africa

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial - The Manila Times

Feb 18, 2025
pulisher
Feb 18, 2025

Major Breakthrough: Galectin's MASH Treatment Cuts Liver Complications by 68% in Latest Trial Data - StockTitan

Feb 18, 2025
pulisher
Feb 15, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Stratos Wealth Partners LTD. - Defense World

Feb 15, 2025
pulisher
Feb 04, 2025

Largest borrow rate increases among liquid names - MSN

Feb 04, 2025
pulisher
Feb 04, 2025

JPMorgan Chase & Co. Grows Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Feb 04, 2025
pulisher
Jan 30, 2025

Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight - The Malaysian Reserve

Jan 30, 2025
pulisher
Jan 29, 2025

Liver Cirrhosis Market Forecasted for Strong Growth from 2025 - openPR

Jan 29, 2025
pulisher
Jan 29, 2025

Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World

Jan 29, 2025
pulisher
Jan 28, 2025

Galectin drops as trial for lead asset fails in MASH - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

Galectin Therapeutics shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria

Jan 28, 2025
pulisher
Jan 25, 2025

Galectin Therapeutics (NASDAQ: GALT) 8-K Filing Reveals Positive Results from NAVIGATE Trial - Defense World

Jan 25, 2025
$20.65
price up icon 0.63%
$70.47
price up icon 1.28%
$32.49
price up icon 0.64%
$23.90
price up icon 1.85%
$108.35
price up icon 3.89%
biotechnology ONC
$247.87
price up icon 1.21%
大文字化:     |  ボリューム (24 時間):